Form 4 Sarepta Therapeutics, For: Aug 05 Filed by: Rodino-Klapac Louise
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
BMO Capital Reiterates Market Perform Rating on Sarepta Therapeutics (SRPT) Following Mgmt. Meeting
August 7, 2025 11:05 AM EDTBMO Capital analyst Kostas Biliouris reiterated a Market Perform rating and $50.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).
The analyst comments "We hosted an investor call with management post 2Q earnings and takeaways include: (1) Management resumed Elevidys infusions following the pause (first infusion on 8/5)... More
